4//SEC Filing
PENG STANFORD L 4
Accession 0001626199-24-000076
CIK 0001626199other
Filed
May 9, 8:00 PM ET
Accepted
May 10, 7:26 PM ET
Size
29.5 KB
Accession
0001626199-24-000076
Insider Transaction Report
Form 4
PENG STANFORD L
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-05-08$13.20/sh+7,025$92,730→ 79,396 total - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−22,593→ 42,407 totalExercise: $11.31Exp: 2028-01-01→ Common Stock (22,593 underlying) - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−26,912→ 81,088 totalExercise: $3.23Exp: 2030-01-22→ Common Stock (26,912 underlying) - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−13,377→ 236,623 totalExercise: $6.33Exp: 2028-09-27→ Common Stock (13,377 underlying) - Exercise/Conversion
Common Stock
2024-05-08$6.51/sh+3,126$20,350→ 82,522 total - Exercise/Conversion
Common Stock
2024-05-08$0.65/sh+161,492$104,970→ 281,281 total - Exercise/Conversion
Common Stock
2024-05-08$0.65/sh+37,267$24,224→ 119,789 total - Exercise/Conversion
Common Stock
2024-05-08$11.31/sh+22,593$255,527→ 303,874 total - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−7,025→ 142,975 totalExercise: $13.20Exp: 2031-01-04→ Common Stock (7,025 underlying) - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−37,267→ 0 totalExercise: $0.65Exp: 2027-03-13→ Common Stock (37,267 underlying) - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−161,492→ 0 totalExercise: $0.65Exp: 2026-09-21→ Common Stock (161,492 underlying) - Exercise/Conversion
Common Stock
2024-05-08$3.23/sh+26,912$86,926→ 330,786 total - Exercise/Conversion
Common Stock
2024-05-08$6.33/sh+13,377$84,676→ 344,163 total - Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−3,126→ 71,874 totalExercise: $6.51Exp: 2029-02-05→ Common Stock (3,126 underlying)
Footnotes (8)
- [F1]Includes 48,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
- [F2]The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- [F3]One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
- [F4]One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
- [F5]One-fourth (1/4) of the shares subject to the option will vest on September 6, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
- [F6]One-fourth (1/4) of the shares subject to the option will vest on January 2, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
- [F7]One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
- [F8]1/2 of the shares subject to the option become vested and exercisable on October 1, 2020 and the balance of the shares subject to the option become vested and exercisable on October 1, 2022, subject to continued service through each such date.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
Related Parties
1- filerCIK 0001711352
Filing Metadata
- Form type
- 4
- Filed
- May 9, 8:00 PM ET
- Accepted
- May 10, 7:26 PM ET
- Size
- 29.5 KB